CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment

Group 1 - CG Oncology Inc. has been identified as a promising stock, with Morgan Stanley raising its price target from $56 to $79 while maintaining an Overweight rating [1][3] - The company is focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for Non-Muscle Invasive Bladder Cancer (NMIBC) [2][4] - Recent clinical trial updates show promising data from the BOND-003 Cohort C trial for high-risk NMIBC patients unresponsive to BCG treatment, and the initiation of the CORE-008 Cohort CX trial [3] Group 2 - CG Oncology's management outlook is bolstered by a strong cash position and a favorable legal outcome, expected to fund operations into the first half of 2028 [2] - Upcoming milestones include the completion of Phase 3 enrollment for the PIVOT-006 trial in Q3 and the initiation of a Biologics License Application submission for cretostimogene in Q4 [3]